Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed · Phase 1/Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Combining celecoxib with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan and docetaxel when given together with celecoxib and to see how well they work in treating patients with advanced non-small cell lung cancer.

Key facts

Study ID

NCT00073866

Run by

Northwestern University

Starts

2003-06-01

Expected to finish

2004-12-01

Last updated by the study team

2012-07-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center at Northwestern University — Chicago, Illinois, United States
• Evanston Northwestern Health Care - Evanston Hospital — Evanston, Illinois, United States
• Silver Cross Hospital — Joliet, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.